The Australian: Cancer trial results prove good medicine for biotech's stocks

17 November 2015

The Australian's Sarah-Jane Tasker reports that "Starpharma's shares have hit a fresh high following positive results in a preclinical trail for its ovarian cancer model. The company said a cancer drug treatment coupled with its dendrimer (DEP) technology - which allows for more effective drug delivery - had resulted in complete tumour regression and 100 per cent survival in a preclinical trial done on mice."

Go to the artice (external link)

About Starpharma

This document contains Forward Looking Statements

For Further Information

© Starpharma Holdings Limited 2017